buyNotable cluster of 4
Carl L Gordon bought $3.7M of KNTE
director, owner at Kinnate Biopharma Inc.. 1,405,168 shares at an average of $2.61, traded Apr 28, 2023, filed May 2, 2023.
Conviction score
60Value
$3.7M
1,405,168 shares
Holdings after
794,368
+255% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +25Trade size$3.7M at market
- +10Relative to holdingsHoldings up 255%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- -5Track recordMedian 6-month excess return -24% over 5 past buys
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000947871-23-000516, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 28, 2023 | POpen-market purchase Common Stockindirect: See footnotes | +60,998 | $2.55 | $156k | 610,998 | May 2, 2023 |
| Apr 28, 2023 | POpen-market purchase Common Stockindirect: See footnotes | +228,754 | $2.55 | $583k | 3,737,784 | May 2, 2023 |
| Apr 28, 2023 | POpen-market purchase Common Stockindirect: See footnotes | +60,997 | $2.55 | $156k | 610,997 | May 2, 2023 |
| May 1, 2023 | POpen-market purchase Common Stockindirect: See footnotes | +124,544 | $2.62 | $326k | 735,542 | May 2, 2023 |
| May 1, 2023 | POpen-market purchase Common Stockindirect: See footnotes | +467,068 | $2.62 | $1.2M | 4,204,852 | May 2, 2023 |
| May 1, 2023 | POpen-market purchase Common Stockindirect: See footnotes | +124,545 | $2.62 | $326k | 735,542 | May 2, 2023 |
| May 2, 2023 | POpen-market purchase Common Stockindirect: See footnotes | +58,826 | $2.67 | $157k | 794,368 | May 2, 2023 |
| May 2, 2023 | POpen-market purchase Common Stockindirect: See footnotes | +220,610 | $2.67 | $589k | 4,425,462 | May 2, 2023 |
| May 2, 2023 | POpen-market purchase Common Stockindirect: See footnotes | +58,826 | $2.67 | $157k | 794,368 | May 2, 2023 |
Related signals
Other insiders at Kinnate Biopharma Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | Kinnate Biopharma Inc. | Foresite Capital Management IV, LLC owner | $5.0M 1,780,000 shares | +90% | |
| 75Notable | Kinnate Biopharma Inc. | James B. Tananbaum director, owner | $5.0M 1,780,000 shares | +90% | |
| 65Notable | Kinnate Biopharma Inc. | Carl L Gordon director, owner | $4.1M 1,460,932 shares | +184% | |
| 65Notable | Kinnate Biopharma Inc. | Orbimed Advisors LLC director, owner | $4.1M 1,460,932 shares | +184% | |
| 60Notable | Kinnate Biopharma Inc. | Orbimed Advisors LLC director, owner | $3.7M 1,405,168 shares | +255% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.